Short answer · Medically reviewed summary · Last updated: 2026-05-08
Polycythemia Vera (PV) is a chronic myeloproliferative neoplasm characterized by the overproduction of red blood cells, historically referred to as Vaquez-Osler disease or primary polycythemia. While older medical literature may use various terms, Polycythemia Vera is the globally accepted clinical name recognized by major health organizations to describe this specific blood cancer. What are the historical and alternative names for Polycythemia Vera? Over the last century, Polycythemia Vera has been described using several terms that reflect its historical understanding.
Polycythemia Vera synonyms
Other names for Polycythemia Vera: synonyms, acronyms and related terms used by doctors and patients.
Polycythemia Vera (PV) is a chronic myeloproliferative neoplasm characterized by the overproduction of red blood cells, historically referred to as Vaquez-Osler disease or primary polycythemia. While older medical literature may use various terms, Polycythemia Vera is the globally accepted clinical name recognized by major health organizations to describe this specific blood cancer.
What are the historical and alternative names for Polycythemia Vera?
Over the last century, Polycythemia Vera has been described using several terms that reflect its historical understanding. Before the molecular discovery of the JAK2 mutation, clinicians often used names based on the physicians who first characterized the clinical presentation. Common historical synonyms you may encounter in older patient records or medical journals include:
- Vaquez-Osler disease
- Osler-Vaquez disease
- Primary polycythemia
- Polycythemia rubra vera
- Splenomegalic polycythemia
Why does Polycythemia Vera have multiple names?
The evolution of medical terminology for Polycythemia Vera stems from a shift toward standardized classification systems. In the past, the condition was grouped under descriptive names based on physical symptoms like an enlarged spleen (splenomegaly). Today, the medical community uses the classification established by the World Health Organization (WHO), which defines Polycythemia Vera as a BCR-ABL1-negative myeloproliferative neoplasm. This shift ensures that patients, researchers, and clinicians use a uniform language, reducing confusion when reviewing diagnostic reports or clinical trial documentation.
What is the official classification of this condition?
For international medical coding and research, Polycythemia Vera is categorized in the following systems to ensure consistency:
- ICD-10/ICD-11: Classified under myeloproliferative neoplasms (Code D45).
- OMIM: Indexed as #263300, reflecting its association with somatic mutations.
- Orphanet: Listed as ORPHA:733, identifying it as a rare disease for international research tracking.
Next steps
- Consult a hematologist or an oncologist to ensure your medical records use the current, standardized terminology.
- Join the 118 members of the DiseaseMaps.org Polycythemia Vera community to share experiences and find peer-to-peer support.
- Review your latest lab reports to confirm that your diagnosis is documented correctly according to the current WHO criteria.
Medical disclaimer: This content is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment.
References
- Orphanet: Rare Disease Database (ORPHA:733).
- NIH Genetic and Rare Diseases Information Center (GARD).
- Online Mendelian Inheritance in Man (OMIM #263300).
- MPN Research Foundation: Clinical Guidelines and Nomenclature.
